A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan
To improve efficacy and minimize toxicity of EGFR inhibition treatment, we developed Ame55, a novel anti-EGFR IgG1 with lower affinity to EGFR than cetuximab (C225) from a human phage library. Ame55 had lower bioactivity than cetuximab in vitro but similar antitumor efficacy as cetuximab in vivo. Mo...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2019/3017360 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399837744693248 |
|---|---|
| author | Weiyi Qiu Chang Zhang Shuang Wang Xiaoyan Yu Qiong Wang Dadi Zeng Peng Du Jinling Ma Yiqiong Zheng Bo Pang Yunzhou Yu Feng Long Xiaobin Pang Zhiwei Sun |
| author_facet | Weiyi Qiu Chang Zhang Shuang Wang Xiaoyan Yu Qiong Wang Dadi Zeng Peng Du Jinling Ma Yiqiong Zheng Bo Pang Yunzhou Yu Feng Long Xiaobin Pang Zhiwei Sun |
| author_sort | Weiyi Qiu |
| collection | DOAJ |
| description | To improve efficacy and minimize toxicity of EGFR inhibition treatment, we developed Ame55, a novel anti-EGFR IgG1 with lower affinity to EGFR than cetuximab (C225) from a human phage library. Ame55 had lower bioactivity than cetuximab in vitro but similar antitumor efficacy as cetuximab in vivo. Moreover, Ame55 was more efficacious than cetuximab in a Lovo cell xenograft tumor model when combined with irinotecan (CPT-11). Ame55 concentrates in the mouse xenograft tumor and has less toxicity than cetuximab in cynomolgus monkeys in an overdose study. |
| format | Article |
| id | doaj-art-a487f8e37a354c5f832b36fd8d4422fc |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-a487f8e37a354c5f832b36fd8d4422fc2025-08-20T03:38:14ZengWileyJournal of Immunology Research2314-88612314-71562019-01-01201910.1155/2019/30173603017360A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with IrinotecanWeiyi Qiu0Chang Zhang1Shuang Wang2Xiaoyan Yu3Qiong Wang4Dadi Zeng5Peng Du6Jinling Ma7Yiqiong Zheng8Bo Pang9Yunzhou Yu10Feng Long11Xiaobin Pang12Zhiwei Sun13Antibody Engineering Group, Beijing Biotechnology Institute, 100071 Beijing, ChinaAntibody Engineering Group, Beijing Biotechnology Institute, 100071 Beijing, ChinaAntibody Engineering Group, Beijing Biotechnology Institute, 100071 Beijing, ChinaAntibody Engineering Group, Beijing Biotechnology Institute, 100071 Beijing, ChinaAntibody Engineering Group, Beijing Biotechnology Institute, 100071 Beijing, ChinaAntibody Engineering Group, Beijing Biotechnology Institute, 100071 Beijing, ChinaAntibody Engineering Group, Beijing Biotechnology Institute, 100071 Beijing, ChinaJoinn Laboratories (China), Co. Ltd, 100176 Beijing, China301 Hospital, 100853 Beijing, ChinaClinical Laboratory, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, 100053 Beijing, ChinaAntibody Engineering Group, Beijing Biotechnology Institute, 100071 Beijing, ChinaAntibody Engineering Group, Beijing Biotechnology Institute, 100071 Beijing, ChinaPharmaceutical Institute, Henan University, 475004 Kaifeng, ChinaAntibody Engineering Group, Beijing Biotechnology Institute, 100071 Beijing, ChinaTo improve efficacy and minimize toxicity of EGFR inhibition treatment, we developed Ame55, a novel anti-EGFR IgG1 with lower affinity to EGFR than cetuximab (C225) from a human phage library. Ame55 had lower bioactivity than cetuximab in vitro but similar antitumor efficacy as cetuximab in vivo. Moreover, Ame55 was more efficacious than cetuximab in a Lovo cell xenograft tumor model when combined with irinotecan (CPT-11). Ame55 concentrates in the mouse xenograft tumor and has less toxicity than cetuximab in cynomolgus monkeys in an overdose study.http://dx.doi.org/10.1155/2019/3017360 |
| spellingShingle | Weiyi Qiu Chang Zhang Shuang Wang Xiaoyan Yu Qiong Wang Dadi Zeng Peng Du Jinling Ma Yiqiong Zheng Bo Pang Yunzhou Yu Feng Long Xiaobin Pang Zhiwei Sun A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan Journal of Immunology Research |
| title | A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan |
| title_full | A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan |
| title_fullStr | A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan |
| title_full_unstemmed | A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan |
| title_short | A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan |
| title_sort | novel anti egfr mab ame55 with lower toxicity and better efficacy than cetuximab when combined with irinotecan |
| url | http://dx.doi.org/10.1155/2019/3017360 |
| work_keys_str_mv | AT weiyiqiu anovelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT changzhang anovelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT shuangwang anovelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT xiaoyanyu anovelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT qiongwang anovelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT dadizeng anovelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT pengdu anovelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT jinlingma anovelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT yiqiongzheng anovelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT bopang anovelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT yunzhouyu anovelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT fenglong anovelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT xiaobinpang anovelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT zhiweisun anovelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT weiyiqiu novelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT changzhang novelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT shuangwang novelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT xiaoyanyu novelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT qiongwang novelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT dadizeng novelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT pengdu novelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT jinlingma novelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT yiqiongzheng novelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT bopang novelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT yunzhouyu novelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT fenglong novelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT xiaobinpang novelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan AT zhiweisun novelantiegfrmabame55withlowertoxicityandbetterefficacythancetuximabwhencombinedwithirinotecan |